Phase III trial of Sci-B-Vac
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Acronyms PROTECT
- Sponsors VBI Vaccines
- 19 Jun 2017 According to a VBI Vaccines media release, the company plans to submit the IND in the second half of 2017, along with the Clinical Trial Applications (CTAs) for Europe and Canada. Additional details will be available at the time the IND and CTA submissions.
- 22 Feb 2017 According to a VBI Vaccines media release, the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada has expressed it's general support to the Phase III clinical program of Sci-B-Vac.
- 10 Feb 2017 New trial record